TELA Bio, Inc. (TELA)
- Previous Close
5.50 - Open
5.50 - Bid 5.63 x 200
- Ask 5.73 x 200
- Day's Range
5.39 - 6.00 - 52 Week Range
4.24 - 11.26 - Volume
98,623 - Avg. Volume
162,080 - Market Cap (intraday)
140.782M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-1.64 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.20
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
www.telabio.comRecent News: TELA
Performance Overview: TELA
Trailing total returns as of 6/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TELA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TELA
Valuation Measures
Market Cap
140.78M
Enterprise Value
144.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.19
Price/Book (mrq)
9.79
Enterprise Value/Revenue
2.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-63.82%
Return on Assets (ttm)
-43.28%
Return on Equity (ttm)
-459.89%
Revenue (ttm)
63.15M
Net Income Avi to Common (ttm)
-40.3M
Diluted EPS (ttm)
-1.64
Balance Sheet and Cash Flow
Total Cash (mrq)
37.14M
Total Debt/Equity (mrq)
297.85%
Levered Free Cash Flow (ttm)
-28.1M
Research Analysis: TELA
Company Insights: TELA
TELA does not have Company Insights